High Evidence (L1-L2)
Candidates that may be prioritised for clinical evaluation
Criteria
| Level | Definition | Clinical meaning |
|---|---|---|
| L1 | Multiple Phase 3 RCTs / systematic reviews | Strong support; clinical use may be considered |
| L2 | Single RCT or multiple Phase 2 trials | Moderate support; validation trials can be designed |
L1 (26 drugs)
| Drug | Indications | Link |
|---|---|---|
| Anastrozole | 6 | View report |
| Aripiprazole | 10 | View report |
| Azathioprine | 10 | View report |
| Bendamustine | 10 | View report |
| Bromfenac | 10 | View report |
| Busulfan | 10 | View report |
| Conestat Alfa | 10 | View report |
| Dapsone | 1 | View report |
| Doxorubicin | 10 | View report |
| Ecallantide | 6 | View report |
| Ezetimibe | 4 | View report |
| Goserelin | 3 | View report |
| Icatibant | 7 | View report |
| Insulin Degludec | 6 | View report |
| Insulin Glulisine | 10 | View report |
| Lemborexant | 1 | View report |
| Letrozole | 10 | View report |
| Olaparib | 1 | View report |
| Paclitaxel | 10 | View report |
| Peginterferon Alfa-2A | 10 | View report |
| Rifabutin | 10 | View report |
| Simvastatin | 8 | View report |
| Temozolomide | 2 | View report |
| Teriflunomide | 1 | View report |
| Viloxazine | 10 | View report |
| Zileuton | 10 | View report |
L2 (29 drugs)
| Drug | Indications | Link |
|---|---|---|
| Albendazole | 3 | View report |
| Bimatoprost | 10 | View report |
| Carboplatin | 10 | View report |
| Cetirizine | 6 | View report |
| Clofarabine | 10 | View report |
| Clozapine | 10 | View report |
| Cyclophosphamide | 5 | View report |
| Desoximetasone | 10 | View report |
| Dorzolamide | 10 | View report |
| Elagolix | 1 | View report |
| Eslicarbazepine | 6 | View report |
| Irinotecan | 1 | View report |
| Latanoprost | 10 | View report |
| Lenalidomide | 6 | View report |
| Mefenamic Acid | 8 | View report |
| Montelukast | 5 | View report |
| Nitroglycerin | 5 | View report |
| Nortriptyline | 2 | View report |
| Pimecrolimus | 4 | View report |
| Propofol | 5 | View report |
| Pseudoephedrine | 3 | View report |
| Regorafenib | 8 | View report |
| Risankizumab | 10 | View report |
| Sodium Oxybate | 6 | View report |
| Sorafenib | 10 | View report |
| Temazepam | 1 | View report |
| Trabectedin | 1 | View report |
| Trazodone | 10 | View report |
| Ustekinumab | 10 | View report |
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)